Latest predictive factor for glaucoma

Article

Quantitative analysis of colour vision defects provides the possibility of follow-up and may be a useful means for detecting early glaucomatous changes in patients with normal visual fields.

Quantitative analysis of colour vision defects provides the possibility of follow-up and may be a useful means for detecting early glaucomatous changes in patients with normal visual fields, according to recent research conducted at the Department of Ophthalmology at the University of Athens.

Ninety nine eyes of 56 patients with ocular hypertension without visual field defects and no hereditary colour deficiencies were followed up for four to six years. Colour vision defects were studied using a computer programme for Farnsworth-Munsell 100 hue test and visual field tests were performed with Humphrey analyser using programme 30-2. The tests were repeated every six months.

Fifty six eyes developed, during the course of the study, visual field defects which were attributed to glaucomatous changes, while the other 43 eyes showed no functional or anatomical changes.

Click here to read the full article.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.